Month: August 2023
Excerpt from the Press Release: PLEASANTON, Calif., July 26, 2023 /PRNewswire/ — Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of RLS. The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center,…
Read More
Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L)*; At 31 Weeks Post-Dose, Phe Level 319 μmol/L With a 59% Reduction from Baseline, Even After Dietary Protein Supplementation Participant 2 Plasma Phe Level Reduction of 49% Change from…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the first patient has been enrolled in the National Institutes of Health-sponsored Phase 1/2…
Read More
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024 Excerpt from the Press Release: WALTHAM, Mass., July…
Read More- « Previous
- 1
- 2
- 3